Menu

China Vows to End Commercial Ivory Trade

Conservationists declare victory as the country agrees to crack down on domestic ivory sales, which have contributed to the near-extinction of elephant species.

Jan 4, 2017
Joshua A. Krisch

PIXABAY, SPONCHIAChina will enforce a new ban on commercial ivory, officials announced on December 30. The ban is set to go into effect by the end of 2017, The New York Times reported, and could cripple the efforts of elephant poachers in Africa, who sell most of their wares to China. “Certainly closing down domestic ivory in China will have a dramatic impact,” John Robinson of the Wildlife Conservation Society told NPR’s The Two-Way. “The Chinese market is the largest ivory market in the world.”

The World Wildlife Foundation estimates that 20,000 elephants are poached each year in Africa, most due to Chinese demand for ivory, the International Business Times reported. Skilled Chinese artisans typically carve the ivory into ornate patterns that can sell for thousands of dollars. China’s current stockpile of legal ivory is estimated to be worth roughly $150 million, The New York Times reported.

Although new ivory has been banned internationally since 1989, prior legislation has done little to slow the lucrative ivory market in China. Since the ban did not technically prohibit ivory taken before 1989, some unscrupulous dealers had exploited this loophole to pass off new ivory as old, pre-ban samples.

Whether China’s promise will reduce  illegal ivory trade remains to be seen, but in the meantime, conservationists are optimistic. “It’s a game changer,” Elly Pepper of the Natural Resources Defense Council told NPR. “[It] could be the pivotal turning point that brings elephants back from the brink of extinction.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!